AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Beam Therapeutics Inc.
Video analysis: BEAM
All videosNo video analysis for this stock yet. Request one from our team.
News: BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPR NewswireNEW YORK, Sept. 10, 2026NEW YORK, Sept.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Traders Buy Large Volume of Beam Therapeutics Call Options (NASDAQ:BEAM)
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders bought 2,316 call options on the company. This represents an increase of approximately 139% compared to the typical daily volume of 968 call options. Beam Therapeutics Trading Down 9.5% Shares of Beam Therapeutics stock opened at
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD).
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.S. Accelerated Approval Beam to Host Investor Webcast Today, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass.
Similar companies
-
Agios Pharmaceuticals, Inc.
AGIO
·
NASDAQ
Compare
-
Denali Therapeutics Inc.
DNLI
·
NASDAQ
Compare
-
Recursion Pharmaceuticals, Inc.
RXRX
·
NASDAQ
Compare
-
ImmunityBio, Inc.
IBRX
·
NASDAQ
Compare
-
Arcus Biosciences, Inc.
RCUS
·
New York Stock Exchange
Compare
-
Cogent Biosciences, Inc.
COGT
·
NASDAQ
Compare